Drug pricing: How are payers reacting to the IRA? | Latham & Watkins LLP

In this podcast, learn how health insurance companies are adapting to the new requirements of the Inflation Reduction Act, including the redesign of Part D.

The U.S. healthcare landscape is undergoing significant changes as the Centers for Medicare & Medicaid Services (CMS) continues to implement the Inflation Reduction Act (IRA). One key stakeholder affected by the IRA drug price negotiations and the redesign of Medicare Part D is health insurers Show more +

In this podcast, learn how health insurance companies are adapting to the new requirements of the Inflation Reduction Act, including the redesign of Part D.

The U.S. healthcare landscape is undergoing significant changes as the Centers for Medicare & Medicaid Services (CMS) continues to implement the Inflation Reduction Act (IRA). One key stakeholder affected by the IRA drug pricing negotiations and the redesign of Medicare Part D is health insurance companies. In this episode of Connected with Latham, we explore how these payers are responding to the IRA, including the new ability for Part D beneficiaries to spread their cost-sharing evenly across the plan year. Magnolia Market Access' Amanda Forys joins Washington, DC-based Partner Chris Schott and Associate Danny Machado to discuss the results of a recent survey on payer trends. In addition to discussing the broader impact of the IRA on the healthcare industry, the conversation also covers potential Part D premium increases and how payers might pass new IRA obligations on to manufacturers.

Learn more: Show less –